Table 2.
Numbers of a cascade of COVID-19 related events with and without vaccination.
| Strategy | Asymptomatic COVID-19 |
Symptomatic COVID-19 |
Hospitalization (days) |
Death |
||||
|---|---|---|---|---|---|---|---|---|
| No. | 1-RR | No. | 1-RR | No. | 1-RR | No. | 1-RR | |
| Vaccination | ||||||||
| Moderna | 96,325 | 0.8578 (0.8569, 0.8588) | 417,891 | 0.8737 (0.8733, 0.8741) | 816,780 | 0.8509 (0.8497, 0.8504) | 8368 | 0.8417 (0.8381, 0.8454) |
| Pfizer | 100,096 | 0.8522 (0.8513, 0.8532) | 418,654 | 0.8734 (0.8730, 0.8738) | 818,076 | 0.8506 (0.8503, 0.8510) | 8381 | 0.8415 (0.8378, 0.8451) |
| AstraZeneca | 156,754 | 0.7686 (0.7673, 0.7699) | 628,858 | 0.8099 (0.8094, 0.8104) | 1,172,640 | 0.7859 (0.7855, 0.7863) | 11,872 | 0.7755 (0.7710, 0.7799) |
| No vaccination | 677,467 | 3,307,633 | 5,476,842 | 52,876 | ||||
RR: relative risk; 1-RR refers to the effectiveness in terms of the reductions of asymptomatic and symptomatic cases, duration of hospitalization, and deaths.